WO2003039468B1 - Antimnemonic therapy for hypermemory syndromes - Google Patents
Antimnemonic therapy for hypermemory syndromesInfo
- Publication number
- WO2003039468B1 WO2003039468B1 PCT/US2002/035524 US0235524W WO03039468B1 WO 2003039468 B1 WO2003039468 B1 WO 2003039468B1 US 0235524 W US0235524 W US 0235524W WO 03039468 B1 WO03039468 B1 WO 03039468B1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- disorder
- drug
- cue
- antimnemonic
- addiction
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
Abstract
The present invention relates to antimnemonic therapy for the treatment of behaviroal disorders such as addiction, obsessive-compulsive disorder, Tourette's Syndrome, post-traumatic stress disorder (PTSD), bipolar disorder, depression, schizophrenia, anxiety disorders and personality disorders. Antimnemonic therapy may involve cue- or psychotherapy-induced reactivation of memories in combination with the administration of antimnemonic drugs.
Claims
1. A method of treating a behavioral disorder, comprising:
(a) presenting a cue associated with said disorder to a patient; and
(b) administering an antimnemonic drug to the patient, said steps (a) and (b) being performed in either order.
2. The method of claim 1 , further including repeating steps (a) and (b) as needed to alleviate symptoms of said disorder.
3. The method of claim 1 wherein said cue is at least one of a visual, olfactory, aural, tactile, or gustatory cue.
4. The method of claim 1 wherein said cue is presented in a clinical environment.
5. The method of claim 1 wherein said cue is part of the patient's natural environment outside of a clinic.
6. The method of claim 1 wherein said behavioral disorder is a hypermcmory disorder.
7. The method of claim 6 wherein said hypermemory disorder is selected from the group consisting of addiction, obsessive-compulsive disorder, Tourette's syndrome, post-traumatic stress disorder (PTSD), bipolar disorder, depression, schizophrenia, anxiety disorders, and personality disorders.
8. The method of claim 7 wherein said hypermemory disorder is addiction.
9. The method of claim 1 wherein said antimnemonic drug is selected from the group consisting of benzodiazepines, NMDA-rcceptor antagonists, gmcocorticoid receptor antagonists, α2-adrenoceptor agonists, β-adrenoceptor antagonists, muscarinic cholinergic antagonists, protein kinase A inhibitors, protein kinase C inhibitors, calcium/calmodulin dependent kinase inhibitors, mitogen-activated protein kinase kinase inhibitors, cyclic adenosine monophosphate response element binding protein inhibitors, nitric oxide synthase inhibitors, and GABA receptor agonists.
10. The method of claim 1 wherein said .mtimnemonic drug is selected from the group consisting of memantine, muscimol, clonidine, metoprolol, atropine, ecopipam, sulpiride, haloperidol, 7-nitroindazole, benztropine, scopolamine, propranolol, deχtromethorphan, midazolam, and lorazepam.
11. The method of claim 10 wherein said antimnemonic drug is memantine.
12. The method of claim 11 wherem said memantine is administered at a dose of between 0.1 and 5 mg/day.
13. The method of claim 1 wherein said antimnemonic drug is administered by a clinician.
14. The method of claim 1 wherein said antimnemonic drug is self-administered by said patient,
15. The method of claim 1 wherein said antimnemonic drug is administered within five hours following said presenting of a cue.
16. The method of claim 15 wherein said antimnemonic drug is administered within thirty minutes following said presenting of a cue.
17. The method of claim 1 wherein said antimnemonic drug is administered up to one hour prior to said presenting of a cue.
18. A method of treating a behavioral disorder, comprising;
(a) reactivating a memory associated with said disorder in a patient; and 25
(b) administering an antimnemonic drug to said patient, said steps (a) and (b) being performed in either order.
19. The method of claim 18, further including repeating said steps (a) and (b) as needed Lo alleviate symptoms or to maintain symptoms in an alleviated state.
20. The method of claim 18 wherein said reactivating is triggered by presenting said patient with a cue associated with said disorder.
21. The method of claim 20 wherein said cue is at least one of a visual, olfactory, aural, tactile, or gustatory cue.
22. The method of claim 18 wherein said reactivating is triggered by psychotherapy.
23. The method of claim 18 wherein said reactivating is triggered by homework.
24. The method of claim 18 wherein said reactivating occurs in a non-clinical environment.
25. The method of claim 18 wherein said behavioral disorder is a hypermemory disorder.
26. The method of claim 25 wherein said hypermemory disorder is a behavioral disorder included in a reward-deficiency syndrome.
27, The method of claim 25 wherein said hypermemory disorder is an addiction.
28. A method of treating an addiction, comprising:
(a) exposing a patient to a cue or cues associated with said addiction;
(b) administering an antimnemonic drug to said patient, said steps (a) and (b) being performed in either order.
29. The method of claim 28 wherein said addiction is selected from the group consistmg 26
of addiction to drugs, gambling, food, sex, thrill-seeking, violence, political power, money, and computer technology.
30. The method of claim 28 wherein said addiction is to a drug.
31. The method of claim 30 wherein said addiction is to alcohol.
32. The method of claim 31 wherein said cue comprises exposure to the smell of alcoholic beverages.
33. The method of claim 30 wherein said drug is selected from the group consisting of alcohol, cocaine, nicotine, Cannabis, an opiate, and an opiate derivative.
34. The method of claim 30 wherein said addiction is to nicotine.
35, The method of claim 34 wherein said cue comprises exposure to cigarette smoke.
36. The method of claim 30 wherein said addiction is to cocaine.
37. The method of claim 36 wherein said cue comprises exposure to a smell of burning baking soda.
38. The method of claim 30 wherein said exposing said patient to a cue comprises exposing the patient to a drug-related stimulus selected from the group consisting of audiotapes, videotapes, actors performing simulated drug administration rituals, drug paraphernalia, and photographs of drug paraphernalia.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA002465869A CA2465869A1 (en) | 2001-11-06 | 2002-11-05 | Antimnemonic therapy for hypermemory syndromes |
| AU2002354041A AU2002354041A1 (en) | 2001-11-06 | 2002-11-05 | Antimnemonic therapy for hypermemory syndromes |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33271301P | 2001-11-06 | 2001-11-06 | |
| US60/332,713 | 2001-11-06 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| WO2003039468A2 WO2003039468A2 (en) | 2003-05-15 |
| WO2003039468A3 WO2003039468A3 (en) | 2003-10-23 |
| WO2003039468B1 true WO2003039468B1 (en) | 2003-11-27 |
Family
ID=23299527
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2002/035524 WO2003039468A2 (en) | 2001-11-06 | 2002-11-05 | Antimnemonic therapy for hypermemory syndromes |
Country Status (3)
| Country | Link |
|---|---|
| AU (1) | AU2002354041A1 (en) |
| CA (1) | CA2465869A1 (en) |
| WO (1) | WO2003039468A2 (en) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8118722B2 (en) | 2003-03-07 | 2012-02-21 | Neuronetics, Inc. | Reducing discomfort caused by electrical stimulation |
| US7153256B2 (en) | 2003-03-07 | 2006-12-26 | Neuronetics, Inc. | Reducing discomfort caused by electrical stimulation |
| TW200531680A (en) * | 2004-03-03 | 2005-10-01 | Merz Pharma Gmbh & Co Kgaa | Therapy using 1-aminocyclohexane derivatives for the treatment of behavioral disorders associated with alzheimer's disease |
| US7601115B2 (en) | 2004-05-24 | 2009-10-13 | Neuronetics, Inc. | Seizure therapy method and apparatus |
| DE602005027714D1 (en) * | 2004-09-20 | 2011-06-09 | Sinai School Medicine | USE OF MEMANTINE (NAMENDA) FOR THE TREATMENT OF AUTISM, FORCED BEHAVIOR AND IMPULSIVITY |
| US7857746B2 (en) | 2004-10-29 | 2010-12-28 | Nueronetics, Inc. | System and method to reduce discomfort using nerve stimulation |
| US7396326B2 (en) | 2005-05-17 | 2008-07-08 | Neuronetics, Inc. | Ferrofluidic cooling and acoustical noise reduction in magnetic stimulators |
| US7824324B2 (en) | 2005-07-27 | 2010-11-02 | Neuronetics, Inc. | Magnetic core for medical procedures |
| WO2008045641A2 (en) * | 2006-10-10 | 2008-04-17 | The University Of Chicago | Composition s comprising a benzodiazepine, an alcohol aversive agent and an abuse aversive agent |
| US20110046120A1 (en) * | 2006-10-26 | 2011-02-24 | Mclean Hospital Corporation | Treatment of impulse control disorders |
| IL292725A (en) * | 2012-07-12 | 2022-07-01 | Emalex Biosciences Inc | Fused benzazepines for treatment of tourette's syndrome |
| WO2016061320A2 (en) * | 2014-10-15 | 2016-04-21 | Rowan University | Timber therapy for post-traumatic stress disorder |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0591434A4 (en) * | 1991-06-26 | 1994-09-14 | Sepracor Inc | Method and compositions for treating emesis, nausea and other disorders using optically pure r(+) ondansetron |
| US5338738A (en) * | 1993-04-19 | 1994-08-16 | Bristol-Myers Squibb Company | Cerebral function enhancers: acyclic amide derivatives of pyrimidinylpiperidines |
| US5863934A (en) * | 1995-09-21 | 1999-01-26 | Amy F. T. Arnsten | Use of lofexidine in the treatment of behavioral disorders |
-
2002
- 2002-11-05 WO PCT/US2002/035524 patent/WO2003039468A2/en not_active Application Discontinuation
- 2002-11-05 AU AU2002354041A patent/AU2002354041A1/en not_active Abandoned
- 2002-11-05 CA CA002465869A patent/CA2465869A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2465869A1 (en) | 2003-05-15 |
| WO2003039468A2 (en) | 2003-05-15 |
| AU2002354041A1 (en) | 2003-05-19 |
| WO2003039468A3 (en) | 2003-10-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zhou et al. | Deep brain stimulation of nucleus accumbens on heroin-seeking behaviors: a case report | |
| WO2003039468B1 (en) | Antimnemonic therapy for hypermemory syndromes | |
| Alam Mehrjerdi | Crystal in Iran: methamphetamine or heroin kerack | |
| US20040087576A1 (en) | Antimnemonic therapy for hypermemory syndromes | |
| Martin et al. | Progress in cue exposure therapy for the treatment of addictive disorders: a review update | |
| Couroux et al. | A birch sublingual allergy immunotherapy tablet reduces rhinoconjunctivitis symptoms when exposed to birch and oak and induces IgG4 to allergens from all trees in the birch homologous group | |
| Fuchs et al. | Basolateral amygdala involvement in memory reconsolidation processes that facilitate drug context‐induced cocaine seeking | |
| JP2009528289A (en) | Methods of modulating neurotransmitter systems by inducing counter adaptation | |
| Maurer et al. | Vaccination against nicotine: an emerging therapy for tobacco dependence | |
| Demaret et al. | Staff concerns in heroin‐assisted treatment centres | |
| Hung et al. | Effect of antidepressants for cessation therapy in betel-quid use disorder: a randomised, double-blind, placebo-controlled trial | |
| Courtwright | The prepared mind: Marie Nyswander, methadone maintenance, and the metabolic theory of addiction | |
| Kummer et al. | Dopamine dysregulation syndrome in Parkinson's disease: case report | |
| Chen et al. | Zolpidem improves akinesia, dystonia and dyskinesia in advanced Parkinson’s disease | |
| Dean et al. | Opiate Receptors and Antagonists | |
| Stutius et al. | Sublingual desensitization for buprenorphine hypersensitivity | |
| Balbani et al. | Recent developments for smoking cessation and treatment of nicotine dependence | |
| Kitchens et al. | Nicotine conjugate vaccines: A novel approach in smoking cessation | |
| Chua et al. | Abuse of prescription buprenorphine, regulatory controls and the role of the primary physician | |
| Niesink et al. | Drugs of Abuse and Addiction: neurobehavioral toxicology | |
| El-Awady et al. | Vardenafil ameliorates immunologic-and non-immunologic-induced allergic reactions | |
| Pentel | Vaccines and depot medications for drug addiction: rationale, mechanisms of action, and treatment implications | |
| Askenase | Gee whiz: CpG DNA allergy therapy! | |
| Kitzman et al. | Substance use disorders in adolescents and young adults: history and perioperative considerations from the society for pediatric pain medicine | |
| CN101269057B (en) | Use of succinic acid as metal disease resistant medicament synergistic agent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| B | Later publication of amended claims |
Free format text: 20030818 |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2465869 Country of ref document: CA |
|
| 122 | Ep: pct application non-entry in european phase | ||
| NENP | Non-entry into the national phase in: |
Ref country code: JP |
|
| WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |